A multicenter, placebo-controlled, double-blind clinical trial assessing the effects of a multicomponent nutritional supplement for treating photoaged skin in healthy women.

Plain-language guide to PMID 27781390 (2017): double-blind randomized controlled trial of Copper (Supplement).

Key Facts

PMID: 27781390
Journal: Journal of cosmetic dermatology
Year: 2017
Study type: Randomized Controlled Trial
Authors: Birnbaum JE et al. (6 authors)
DOI: 10.1111/jocd.12290

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Evaluate a multicomponent nutritional supplement on photoaged skin.

Why It Was Studied

Dietary or supplementary intake of nutrients and other ingredients positively affects skin appearance.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, women only.

The primary endpoint was Investigator Global Assessment of overall facial appearance at week 24.

Secondary endpoints included investigator- and subject-rated assessments of the face, décolletage, and hands; facial photography assessments (conducted by an independent panel of dermatologists); and instrumental measures.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

More than one site took part, so the participants came from several places.

What Was Measured

PubMed files the paper under topics including Dietary Supplements, Face, Hand, Neck, Photography and Skin Aging.

Author keywords: antioxidants, marine complex and photoaging.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Journal of cosmetic dermatology), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Copper (Supplement) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.